Table 1: Adjuvant interferon studies.

Study namePatientsType of sarcomaType of interferonDose/scheduleOutcome

Karolinska Hospital seriesAfter surgical resection, 89 patients OsteosarcomaInterferon-αCohort 1 (70 patients) 3 × 106 IU daily ×1 month, followed by 3×/week, 17 months
Cohort 2 (19 patients) 3 × 106 IU daily for 3–5 years
10-year metastatic free survival: 39% (95% CI 29–49%)
10-year sarcoma specific survival: 43% (95% CI 33–54%) [65, 66]
Median time to metastasis 8 months (range 1–60 months)
value not specified

COSS-80
100 patients after preoperative chemotherapy and surgical resection were randomized +/− interferon OsteosarcomaInterferon-β100,000 U/kg for 22 weeks (2 injections weekly ×2 weeks, daily ×4 weeks, weekly ×16 weeks)30-month continuous disease-free survival: 77% interferon arm versus 73% noninterferon arm [67]
Log rank test,

EURAMOS 1715 patients that had good response to preoperative chemotherapy were randomized to postoperative chemotherapy +/− interferonOsteosarcomaPegylated interferon-α2b0.5–1.0 μg/kg/week for 2 yearsPrimary endpoint: event-free survival (EFS) [68]
77% who received INT were disease free at 3 years compared to 74%
Hazard ratio for EFS from adjusted Cox model was 0.82 (95% CI 0.61–1.11; ) in favor of chemotherapy + interferon